Literature DB >> 31029910

Immunological goals for respiratory syncytial virus vaccine development.

Barney S Graham1.   

Abstract

Defining the immunological goals for respiratory syncytial virus (RSV) vaccination requires understanding of RSV biology and tropism, mechanisms of cell-to-cell spread and immunity, epidemiology, and transmission dynamics. The immunological goals for a particular vaccine would be product-specific based on antigen selection, delivery approach, and target population. There are many ways to achieve immunity against RSV infection involving innate and adaptive responses, humoral, and cellular effector mechanisms, and mucosal and systemic responses. Both protective and pathological immune response patterns have been demonstrated in animal models and humans. In this short commentary, the entire information matrix that may inform the design of particular vaccine candidates cannot be fully reviewed, but the rationale behind the major vaccine approaches in key target populations will be discussed. Published by Elsevier Ltd.

Entities:  

Year:  2019        PMID: 31029910     DOI: 10.1016/j.coi.2019.03.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  10 in total

1.  Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.

Authors:  Michiel van Boven; Anne C Teirlinck; Adam Meijer; Mariëtte Hooiveld; Christiaan H van Dorp; Rachel M Reeves; Harry Campbell; Wim van der Hoek
Journal:  J Infect Dis       Date:  2020-10-07       Impact factor: 5.226

2.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 3.  The journey to a respiratory syncytial virus vaccine.

Authors:  Asuncion Mejias; Rosa Rodríguez-Fernández; Silvia Oliva; Mark E Peeples; Octavio Ramilo
Journal:  Ann Allergy Asthma Immunol       Date:  2020-03-23       Impact factor: 6.347

4.  A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.

Authors:  Vincent Pavot; Hélène Bisceglia; Florine Guillaume; Sandrine Montano; Linong Zhang; Florence Boudet; Jean Haensler
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

5.  Convergent structural features of respiratory syncytial virus neutralizing antibodies and plasticity of the site V epitope on prefusion F.

Authors:  Wayne Harshbarger; Sai Tian; Newton Wahome; Ankita Balsaraf; Deep Bhattacharya; Desheng Jiang; Ratnesh Pandey; Kunal Tungare; Kristian Friedrich; Nurjahan Mehzabeen; Marco Biancucci; Diana Chinchilla-Olszar; Corey P Mallett; Ying Huang; Zihao Wang; Matthew James Bottomley; Enrico Malito; Sumana Chandramouli
Journal:  PLoS Pathog       Date:  2020-11-02       Impact factor: 6.823

6.  Two RSV Platforms for G, F, or G+F Proteins VLPs.

Authors:  Binh Ha; Jie E Yang; Xuemin Chen; Samadhan J Jadhao; Elizabeth R Wright; Larry J Anderson
Journal:  Viruses       Date:  2020-08-19       Impact factor: 5.048

7.  A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.

Authors:  Baoshan Zhang; Cara W Chao; Yaroslav Tsybovsky; Olubukola M Abiona; Geoffrey B Hutchinson; Juan I Moliva; Adam S Olia; Amarendra Pegu; Emily Phung; Guillaume B E Stewart-Jones; Raffaello Verardi; Lingshu Wang; Shuishu Wang; Anne Werner; Eun Sung Yang; Christina Yap; Tongqing Zhou; John R Mascola; Nancy J Sullivan; Barney S Graham; Kizzmekia S Corbett; Peter D Kwong
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.996

8.  Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.

Authors:  Wayne Harshbarger; Priyanka D Abeyrathne; Sai Tian; Ying Huang; Sumana Chandramouli; Matthew James Bottomley; Enrico Malito
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 9.  Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.

Authors:  Zifang Shang; Shuguang Tan; Dongli Ma
Journal:  Int J Biol Sci       Date:  2021-09-27       Impact factor: 6.580

10.  Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.

Authors:  Patricia T Campbell; Nicholas Geard; Alexandra B Hogan
Journal:  BMC Med       Date:  2020-11-12       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.